Plus Therapeutics (PSTV) Competitors $0.67 +0.02 (+3.18%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PSTV vs. XAIR, QTI, VVOS, LFWD, PETV, IRIX, NMTC, ALUR, NRXS, and ICUShould you be buying Plus Therapeutics stock or one of its competitors? The main competitors of Plus Therapeutics include Beyond Air (XAIR), QT Imaging (QTI), Vivos Therapeutics (VVOS), ReWalk Robotics (LFWD), PetVivo (PETV), IRIDEX (IRIX), NeuroOne Medical Technologies (NMTC), Allurion Technologies (ALUR), NeurAxis (NRXS), and SeaStar Medical (ICU). These companies are all part of the "medical equipment" industry. Plus Therapeutics vs. Beyond Air QT Imaging Vivos Therapeutics ReWalk Robotics PetVivo IRIDEX NeuroOne Medical Technologies Allurion Technologies NeurAxis SeaStar Medical Plus Therapeutics (NASDAQ:PSTV) and Beyond Air (NASDAQ:XAIR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, risk, valuation, profitability, media sentiment, analyst recommendations, earnings, institutional ownership and dividends. Do insiders & institutionals have more ownership in PSTV or XAIR? 3.3% of Plus Therapeutics shares are owned by institutional investors. Comparatively, 31.5% of Beyond Air shares are owned by institutional investors. 5.5% of Plus Therapeutics shares are owned by company insiders. Comparatively, 20.1% of Beyond Air shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Do analysts rate PSTV or XAIR? Plus Therapeutics presently has a consensus target price of $11.17, indicating a potential upside of 1,615.31%. Beyond Air has a consensus target price of $3.67, indicating a potential upside of 1,494.90%. Given Plus Therapeutics' higher possible upside, analysts plainly believe Plus Therapeutics is more favorable than Beyond Air.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Plus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Beyond Air 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the media prefer PSTV or XAIR? In the previous week, Beyond Air had 3 more articles in the media than Plus Therapeutics. MarketBeat recorded 6 mentions for Beyond Air and 3 mentions for Plus Therapeutics. Beyond Air's average media sentiment score of 0.40 beat Plus Therapeutics' score of 0.29 indicating that Beyond Air is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Plus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Beyond Air 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is PSTV or XAIR more profitable? Plus Therapeutics has a net margin of -225.07% compared to Beyond Air's net margin of -1,730.00%. Plus Therapeutics' return on equity of 0.00% beat Beyond Air's return on equity.Company Net Margins Return on Equity Return on Assets Plus Therapeutics-225.07% N/A -154.56% Beyond Air -1,730.00%-226.01%-109.75% Which has preferable earnings and valuation, PSTV or XAIR? Plus Therapeutics has higher revenue and earnings than Beyond Air. Plus Therapeutics is trading at a lower price-to-earnings ratio than Beyond Air, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPlus Therapeutics$4.91M2.25-$13.32M-$2.50-0.26Beyond Air$3.02M5.23-$60.24M-$1.06-0.22 Which has more risk & volatility, PSTV or XAIR? Plus Therapeutics has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Comparatively, Beyond Air has a beta of 0.15, suggesting that its share price is 85% less volatile than the S&P 500. Does the MarketBeat Community prefer PSTV or XAIR? Plus Therapeutics received 23 more outperform votes than Beyond Air when rated by MarketBeat users. However, 69.57% of users gave Beyond Air an outperform vote while only 63.39% of users gave Plus Therapeutics an outperform vote. CompanyUnderperformOutperformPlus TherapeuticsOutperform Votes7163.39% Underperform Votes4136.61% Beyond AirOutperform Votes4869.57% Underperform Votes2130.43% SummaryBeyond Air beats Plus Therapeutics on 10 of the 17 factors compared between the two stocks. Remove Ads Get Plus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PSTV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PSTV vs. The Competition Export to ExcelMetricPlus TherapeuticsSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.07M$4.07B$5.33B$7.57BDividend YieldN/A39.49%5.11%4.32%P/E Ratio-0.2627.6321.6617.82Price / Sales2.2550.21377.4894.61Price / CashN/A51.0838.1534.64Price / Book-2.175.826.454.00Net Income-$13.32M$67.09M$3.20B$247.23M7 Day Performance-22.48%-0.17%2.83%1.44%1 Month Performance-4.10%-3.20%-8.58%-6.26%1 Year Performance-62.80%14.84%10.35%0.59% Plus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PSTVPlus Therapeutics1.7246 of 5 stars$0.67+3.2%$11.17+1,562.4%-62.6%$11.42M$4.91M-0.2720Short Interest ↑Gap DownXAIRBeyond Air4.2178 of 5 stars$0.24-2.3%$3.67+1,453.0%-82.3%$16.24M$3.02M-0.2270News CoverageGap UpQTIQT ImagingN/A$0.56+1.8%N/A-43.5%$15.20M$4.00M0.00N/AVVOSVivos Therapeutics1.75 of 5 stars$2.52-1.2%$6.30+150.0%-20.9%$14.84M$14.58M-0.44160Analyst ForecastNews CoverageGap DownLFWDReWalk Robotics2.6193 of 5 stars$1.37-6.8%$9.00+556.9%-71.6%$14.56M$25.66M-0.5560Short Interest ↓News CoverageGap DownPETVPetVivoN/A$0.61flatN/A-16.6%$14.51M$1.05M-1.3620News CoverageGap DownIRIXIRIDEX1.3239 of 5 stars$0.85-1.4%$2.00+135.3%-68.5%$14.27M$48.67M-1.27120Gap UpHigh Trading VolumeNMTCNeuroOne Medical Technologies0.7707 of 5 stars$0.43-8.8%N/A-51.8%$13.37M$5.75M-1.6720High Trading VolumeALURAllurion Technologies2.2525 of 5 stars$2.74-5.5%$22.83+733.3%-96.0%$13.14M$32.11M-0.23501Short Interest ↑Negative NewsGap DownNRXSNeurAxisN/A$1.75-5.7%N/A-44.3%$12.59M$2.69M-0.9519ICUSeaStar Medical0.1168 of 5 stars$1.34-3.6%N/A-92.2%$11.69M$135,000.00-0.122Short Interest ↑Gap Up Remove Ads Related Companies and Tools Related Companies Beyond Air Competitors QT Imaging Competitors Vivos Therapeutics Competitors ReWalk Robotics Competitors PetVivo Competitors IRIDEX Competitors NeuroOne Medical Technologies Competitors Allurion Technologies Competitors NeurAxis Competitors SeaStar Medical Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PSTV) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Plus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Plus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
